Type 2 & other diabetes

Prognostic value of lipoprotein(a) for cardiovascular events after lower limb revascularization in diabetic patients with chronic limb-threatening ischemia

Cardiovasc DiabetolPublished Prospective cohort study

Authors' conclusion

This study demonstrated that Lp(a) is a strong independent predictor of both cardiovascular and limb events in patients with T2DM undergoing LER for CLTI. These findings support the potential role of Lp(a) as a marker of residual risk in this high-risk population and suggest its utility in risk stratification.

Study context

Population
Patients with T2D and chronic limb-threatening ischemia undergoing lower extremity revascularization
Participants
158 patients
Exposure
Patients with events vs without events levels)
  • Eventsn = 74
Outcome
MACE, major adverse limb events (MALE), or both
Follow-up
12 months

Main finding

As reported in the abstract

Composite events (MACE, MALE, or both); Lp(a) as predictor

P < 0.01

Patients with events (major adverse cardiovascular events (MACE), major adverse limb events (MALE), or both)
74 patients (46.8%)
Lp(a) independently associated with adverse events, HR
1.07 (95% CI 1.04-1.10; p < 0.01)
Lp(a) cutoff 29.6 mg/dL: increased risk of events (p < 0.01)
3.8-fold
AUC of base clinical model with vs without Lp(a), composite outcome (p < 0.01)
from 0.74 to 0.98

Observational data: associations, not effects.

Further findings

MACE

Elevated Lp(a), multivariable HR
1.08 (95% CI 1.03-1.13; p < 0.01)
AUC improvement with Lp(a) added to base model (p = 0.03)
from 0.81 to 0.89
  • Multivariable analysis

MALE

Elevated Lp(a), multivariable HR
1.05 (95% CI 1.02-1.07; p < 0.01)
AUC improvement with Lp(a) added to base model (p < 0.01)
from 0.78 to 0.92
  • Multivariable analysis

Original publication

Prognostic value of lipoprotein(a) for cardiovascular events after lower limb revascularization in diabetic patients with chronic limb-threatening ischemia. Cardiovasc Diabetol. Published 10 July 2025. doi:10.1186/s12933-025-02833-2

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.